Personalis, Inc. (PSNL)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$17.20+2.20%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · PSNL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 26.5% |
| Our one-year growth estimate | diamond | 41.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 14.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 32 industry peers · Company calendar date is not available
PSNL — earnings miss
Dated 2026-08-04
Results of Operations and Financial Condition. On August 4, 2026, Personalis, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchang…
Why it matters: Using more cash may show financial strain. This could affect future investments.
Worry ifCash usage exceeds $100 million by the end of 2026.
Less concerning ifCash usage remains at or below $100 million by the end of 2026.
Why it matters: Meeting this target would confirm strong adoption of Personalis' MRD tests.
Supportive ifClinical test volumes are reported at or above 43,000.
Worry ifClinical test volumes are below 43,000.
Why it matters: Faster clinical volume growth helps Personalis grow. It shows they can make more money.
Supportive ifManagement says clinical volume growth has gone up a lot.
Worry ifManagement says clinical volume adoption is flat or going down.
Why it matters: Going above this number shows strong growth and supports management's plans.
Supportive ifQ2 revenue reported above $22.4 million.
Worry ifQ2 revenue reported below $22.4 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$305 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $876 loss on $10,000 · 8.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,520 loss on $10,000 · 55.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Monitoring cash usage is important as it impacts financial health. High cash burn could signal trouble.
Worry ifManagement reports cash use is below $100M for 2026. This shows better cash management.
Less concerning ifManagement says they are using over $100M in cash. This raises worries about staying strong.
Why it matters: New coverage could greatly increase clinical test volume and revenue.
Supportive ifNew Medicare coverage is announced for more types of cancer.
Worry ifNo new Medicare coverage announcements will come in the next quarter.
Why it matters: More clinics using the service is key for Personalis. It shows they can grow.
Supportive ifManagement says there is a large increase in how many clinics are using it.
Worry ifClinical volume adoption metrics are flat or down. This shows ongoing challenges.
Why it matters: This report will show if Personalis can improve its financial performance. Investors will look for signs of recovery.
Watch forThe earnings report shows revenue growth is speeding up again. It is moving back to earlier highs.
Also watch forEarnings report shows continued revenue decline or losses.
Why it matters: The health care sector is slowing. If revenue growth re-accelerates, it could help Personalis.
Supportive ifHealth care sector revenue growth shows a return to near 10 percent.
Worry ifSector revenue growth continues to decline or remains below 10 percent.
Why it matters: Keeping revenue guidance shows trust in growth and operations.
Supportive ifQuarterly revenue stays between $78M and $80M.
Worry ifQuarterly revenue falls below the lower end of the guidance range.
Why it matters: A 500% rise in clinical revenue shows strong demand for NeXT Personal tests. This growth shows Personalis is doing well.
Supportive ifClinical revenue was over $10 million in Q3 2026.
Worry ifClinical revenue growth is under 400% from last year.
Why it matters: The merger could improve Personalis' skills and market position. A good integration may speed up growth.
Supportive ifThe merger will close by early 2027 after getting all approvals.
Worry ifThe merger is delayed or stopped due to regulatory problems.
Why it matters: New Medicare coverage would prove NeXT Personal tests are useful and help revenue grow. It shows acceptance in healthcare.
Supportive ifAnnouncement of Medicare coverage for at least one new use for NeXT Personal.
Worry ifThere are no new Medicare coverage announcements for the next quarter.
Why it matters: A slowdown in clinical test volume growth may mean the market is full or demand is down. This could hurt growth.
Worry ifClinical test volume growth is below 20% from last year in Q3 2026.
Less concerning ifClinical test volume growth stays above 30% from last year.